Skip to main content
$0.049 0.007 (16.67%)

High

$0.05

Low

$0.04

Trades

74

Turnover

$48,318

Volume

1,094,468
30 June 2023 at 4:10pm
If you were already registered, log in here.

Short Interest

ASIC data, 12 Jul 2023

% Shorted

0.00%
vs 0.00% prior report

Most Shorted Rank

672nd
of 711 shorted ASX stocks

Peak Short

4.88%
Apr 2013

Days to Cover

0.0
at 50d avg vol
Subject
PXS Ann: Appendix 4C - quarterly

PXS Ann: Appendix 2A - Exercise of Employee Options

PXS Ann: Section 708A(5)(e) Notice

PXS Ann: Becoming a substantial holder

PXS Ann: Appendix 2A

PXS Ann: Sale of Russian Distribution Rights

PXS Ann: Investor Presentation Capital Raising and Growth Outlook

PXS Ann: Proposed issue of Securities - PXS

PXS Ann: Placement

PXS Ann: Trading Halt

PXS Ann: Investor Presentation

PXS Ann: Appendix 2A - Exercise of Employee Options

PXS Ann: Clinical Trial of Treatment to Prevent Wound and Burns Scars

PXS Ann: US Commercial Launch of Bronchitol

PXS Ann: First Patient Enrolled - Clinical Trial for Cancer Treatment

PXS Ann: Appendix 2A - Exercise of Employee Options

PXS Ann: Half Yearly Report and Accounts

PXS Ann: Pharmaxis Exports CF Drug to US - US$3 Million Milestone

PXS Ann: Appendix 4C - quarterly

PXS Ann: Quarterly Activity Report - December 2020

PXS Ann: Pharmaxis Receives US$7m milestone from Chiesi

PXS Ann: Appendix 2A - exercise of employee options

PXS Ann: Pharmaxis to Present at Proactive CEO Investor Session

PXS Ann: Change in substantial holding

PXS Ann: Change of Director's Interest Notice

PXS Ann: Change of Director's Interest Notice

PXS Ann: Appendix 3G - Employee Options

PXS Ann: Appendix 3G - Employee Options

PXS Ann: Results of Meeting

PXS Ann: Results of Meeting

PXS Ann: CEO Presentation to AGM

PXS Ann: CEO Presentation to AGM

PXS Ann: Chairman's Address to Shareholders

PXS Ann: Chairman's Address to Shareholders

PXS Ann: Ceasing to be a substantial holder from Arix Bioscience

PXS Ann: MEDIA RELEASE BRONCHITOL FDA and MF Trial

PXS Ann: Investor Presentation

PXS Ann: Investor Teleconference

PXS Ann: Pharmaxis Prioritises Clinical Program on Myelofibrosis

PXS Ann: FDA Approves Bronchitol for US Market

PXS Ann: Appendix 4C - quarterly

PXS Ann: September Quarter 2020 Activity Report

PXS Ann: Change in substantial holding from Arix Bioscience

PXS Ann: Change in substantial holding

PXS Article: ASX to open lower but Nasdaq races to another record

If you were already registered, log in here.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL
S88
MAV
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS
MBM